DL-TBOA ammonium
| Code | Size | Price |
|---|
| TAR-T39510-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC 50 s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1) , EAAT2 and EAAT3 , respectively. DL-TBOA ammonium inhibits the uptake of [ 14 C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks EAAT4 and EAAT5 in a competitive manner with K i values of 4.4 μM and 3.2 μM, respectively.
CAS:
2093503-71-8
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-?-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.
Yumiko Sekiya, et al. Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate in rats. Eur J Pharmacol. 2004 Feb 6;485(1-3):201-10.
Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.